AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03851952 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optilume Drug Coated Balloon
Description: The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
Study NCT03678857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants will resistance train their left arm and left leg one day and their right arm and right leg the next day. Participants will supplement with creatine BEFORE one of the training days (randomized to either left or right side) and on the opposite training day (opposite side of the body to the previous training day) supplement with creatine AFTER training. Having the same person in both conditions will control for genetics, habitual diet, other daily activities, and so on, that may have confounded previous research. Muscle mass and strength changes will be measured in each limb prior to and following 8 weeks of training to determine whether creatine timing influenced muscle growth.~Research Question: To determine whether creatine supplementation timing (i.e., before versus after training) effects 8 weeks of resistance training adaptations (i.e., muscle growth and strength changes).
Study NCT03111108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBR/GZR (50 mg/100 mg) FDC
Description: One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
Study NCT03245333 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Recombinant Human Growth Hormone Injection
Description: Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.
Study NCT03245333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Growth Hormone Injection
Description: Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.
Study NCT03245333 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Recombinant Human Growth Hormone Injection
Description: Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.
Study NCT00397735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: amniocentesis
Description: Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.
Study NCT00397735 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: amniocentesis
Description: Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.
Study NCT00397735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine or placebo
Description: Only women with amniocentesis results consistent with infection/inflammation will be randomized
Study NCT00397735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine or placebo
Description: Only women with amniocentesis results consistent with infection/inflammation will be randomized
Study NCT02579226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2811
Description: The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
Study NCT01070745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours
Study NCT01070745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
Study NCT00936351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses. This intervention has been adapted from mindfulness based stress reduction treatment.
Study NCT00936351 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group (control)
Description: A support group during which participants can discuss with each other any issues, problems, or successes at work will be conducted as the control portion.
Study NCT00165919 — intervention group
Intervention type: OTHER
Intervention: None. Not a clinical trial. Specimens taken for basic research in laboratory.
Study NCT03092167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercises
Description: Physical exercises
Study NCT02385760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-4430
Study NCT02385760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04202705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD1875
Description: SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
Study NCT03807830 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electrocochlography
Description: Intra-operative ECochG recording via the implant, post operative ECochG measurements. Impedances measured over time.
Study NCT00530348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
Study NCT00530348 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
Study NCT03256149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT03256149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (IV placebo)
Study NCT00457964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 5 and 10 mg/day or 30, 50, 70mg/week
Study NCT02855515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short-time diagnostic anaesthesia
Description: Patients will undergo a short-time general anaesthesia in order to diagnose Obstructive Sleep Apnoea when relaxed.
Study NCT01747018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich Plasma
Study NCT02699216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation of the Retina
Description: Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.
Study NCT02699216 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrical Stimulation of the Retina
Description: Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.
Study NCT03169751 — intervention group
Intervention type: DEVICE
Intervention: Brain Sentinel Monitoring and Alerting System
Description: The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities during periods of rest. The device is to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures and to provide an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
Study NCT03371771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteer-delivered Behavioral Activation
Description: Behavioral Activation as delivered by trained volunteers
Study NCT03371771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MSW-delivered Behavioral Activation
Description: Behavioral Activation as delivered by trained MSWs
Study NCT01897376 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pfannenstiel incision
Description: Pfannenstiel incision at time of cesarean section
Study NCT01897376 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: vertical skin incision
Description: vertical skin incision at time of cesarean section
Study NCT01415739 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT06693349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the effect of apexification in treatment of contaminated and uncontaminated immature permanent teeth
Description: this procedure was anticipated to be replaced by other procedure be used in this study
Study NCT03399747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abb-R-CHOP
Description: Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma~3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy
Study NCT04437823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Infusions of Stem Cells
Description: Cultured stem cells will be injected at days 1, 3 and 5 intravenously. While patients will be monitored and evaluated for various hematological and organ functions at baseline (day 0) and days 1, 3, 5, 7, 14, 21 and 30
Study NCT03662529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four-Session Mind Freedom Plan
Description: Problem-solving-focused individualized cognitive behavioral therapy (CBT) that featured homework-worksheets to reinforce session-concepts.
Study NCT03662529 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual therapy
Description: Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed.
Study NCT02621853 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Raman spectroscopy of the liver
Description: Liver will be illuminated by the Raman spectroscope optic probe in order to assess fat content
Study NCT03654326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant tablet 45 mg taken orally
Study NCT03654326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching gefapixant tablet taken orally
Study NCT03654326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching gefapixant tablet taken orally
Study NCT04194216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg.
Description: Treatment Arm A
Study NCT03654326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator
Study NCT03654326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator
Study NCT04194216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative single dose (iv) of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg (every 4 hours) or clindamycin 150mg(every 6 hours) for 3 days
Description: Treatment Arm B
Study NCT02448342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Dielectric Sensing (ReDS) Wearable System
Description: The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
Study NCT02448342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Dielectric Sensing (ReDS) Wearable System
Description: The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
Study NCT01834482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified Atkins diet
Description: Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.
Study NCT01834482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: KetoCal
Description: Patients will receive a KetoCal 4:1 ratio (fat: carbohydrates and protein) liquid daily for the first month (if randomized to this arm of the study). They will also be started on the modified Atkins diet.
Study NCT03626662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 890
Description: Ascending Single Doses of AMG 890
Study NCT03626662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Calculated volume to match experimental drug.
Study NCT05826301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation in tibial nerve
Description: The procedure consisted in the application of a square wave biphasic electrical current, with 2-4 Hz frequency, 450 μs pulse during 25 minutes with a needle (0.30mm x 40 mm) inserted proximal to the surface on the tibial nerve.
Study NCT05826301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous electrolysis
Description: The procedure consist on placed a needle (0.30mm x 40 mm) on the most hyperalgesic plantar fascia location with a galvanic current of 3mA, 3 times during 3 seconds.~1 time per weeK
Study NCT03213548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alar facial groove incision
Description: All procedures related to alterations in the alar base will be based on an algorithm proposed by 2010 Adamnson et al lar Soft-Tissue Techniques in Rhinoplasty Algorithmic Approach, Quantifiable Guidelines, and Scar Outcomes From a Single Surgeon Experience ,published at Archives Facial Plastic Surgery in which a sequential approach is used, evaluating step-by-step surgical needs. Initially, the alar base can be reduced by removing tissue from the nasal sill. At this step, modifications at the shape or the width of the nostrils can be done. After that, a rotation-advancement flap is made, and the sill defect is closed. The nasal flair is then assessed and tissue from the alar border can be removed if needed. The incisions not spare the alar facial groove.
Study NCT03213548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alar facial groove spared
Description: The technique is the same of the Alar facial groove incision intervention group, but the incisions spare the groove. The incisions will be at 1 mm above the groove.
Study NCT04142658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 MG
Description: For patients that do NOT meet the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)
Study NCT04142658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG
Description: For patients that meet at least 2 of the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)
Study NCT04142658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Active Control Intervention
Study NCT03844815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered intravenously at a dose of 20mg per day for 10 days during Cycle 1 (28 day cycle)~Decitabine will be administered intravenously at a dose of 20mg per day for 10 days of Cycle 2 (28 day cycle).~Decitabine will be administered intravenously at a dose of 20mg per day for 5 days of each 28 day maintenance cycle
Study NCT03844815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax administered orally on days 1-21 of cycle 1, cycle 2 and maintenance (28 day cycles). Dose levels will be assigned at time of enrollment anywhere from 100mg-400mg. Dose escalation will follow the 3+3 study design.
Study NCT01613196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography with 18F-Fluoro-deoxy-glucose
Description: 2 or 3 FDG-PET scans will be performed in all patients : at inclusion\*, end of treatment and 6 months after completion of treatment in cases of persistent uptake~\*except if already done in the last 15 days.
Study NCT06641440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: patients will be treated for three months in the two groups with the two different protocols for three months both
Study NCT06641440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: patients will be treated for three months in the two groups with the two different protocols for three months both
Study NCT03495635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Big Brothers Big Sisters Community-Based Mentoring Program
Description: One-to-one mentoring provided by an adult volunteer with training and ongoing monitoring and support from program staff.
Study NCT04769778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80Mg Oral Tablet
Description: treatment with 80mg /day of valsartan
Study NCT04589312 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care vaccines
Description: Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)
Study NCT04589312 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostagen, (BioNet-Asia)
Description: Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);
Study NCT02139800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained Inflation
Description: The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds
Study NCT01225224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral
Study NCT02139800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention
Study NCT01225224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01409200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Given per standard of care
Study NCT01409200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiandrogen Therapy
Description: Given per standard of care
Study NCT01409200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO
Study NCT01409200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study NCT01409200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study NCT01409200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional Lymph Node Dissection
Description: Undergo pelvic lymph node dissection
Study NCT01409200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Lymph Node Dissection
Description: Undergo pelvic lymph node dissection
Study NCT05533476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi Sensory Stimulation and Priming
Description: In the MuSSAP intervention group, the infant wears a multisensory stimulating wristband aiming at increasing attention for the affected upper limb and readiness to initiate a goal-directed movement. Parents are instructed to present a toy to their child if the child shows attention to the affected arm and hand. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
Study NCT03850574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuspetinib
Description: Daily (QD), continuous dosing